-
C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory studyBuzzetti, Raffaella ...OBJECTIVE: To investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting beta-cell function evaluated by C-peptide secretion in recent-onset ... type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Data were collected from type 1 diabetic subjectsenrolled in multicenter phase II studies with a randomized, double-blind, and placebo-controlled design in whom fasting and stimulated C-peptide levels were measured. HLA genotypes were classified in high, moderate, and low risk categories. RESULTS: A total of 146 subjects (aged 4.3 to 58.5 years) were enrolled, including 76 children (<18 years old) and 70 adults. At baseline, there was a significant increase in fasting, maximal, andarea under the curve (AUC) C-peptide from high to moderate and low risk HLAgenotypes in adults (P for trend <0.04) but not in children. Children showed a decrease of the three parameters over time regardless of therapy and HLA genotype. DiaPep277-treated adults with low risk genotype had significantly higher maximal and AUC C-peptide versus placebo at 12 months (0.04 +/- 0.07 vs. -0.28 +/- 0.09 nmol/L, P < 0.01, and 0.53 +/- 1.3 vs. -4.59+/- 1.5 nmol/L, P < 0.05, respectively). In the moderate risk genotype group, Deltamaximal and AUC C-peptide values were significantly higher in DiaPep277-treated versus placebo-treated patients (P < 0.01 and P < 0.05, respectively). CONCLUSIONS: This exploratory study demonstrates that type 1 diabetic adults with low and moderate risk HLA genotypes benefit the most fromintervention with DiaPep277; the only subgroup with an increase of C-peptide at 12 months after diagnosis was the low risk DiaPep277-treated subgroup.Source: Diabetes. - ISSN 0012-1797 (Vol. 60, no. 11, 2011, str. 3067-3072)Type of material - article, component partPublish date - 2011Language - englishCOBISS.SI-ID - 29623513
Author
Buzzetti, Raffaella |
Cernea, Simona |
Petrone, Antonio |
Capizzi, Marco |
Spoletini, Marialuisa |
Zampetti, Simona |
Guglielmi, Chiara |
Venditti, Chiara |
Pozzilli, Paolo |
Battelino, Tadej
Topics
Genes, MHC Class II |
Diabetes Mellitus, Insulin-Dependent |
C-Peptide |
Immunotherapy |
Genotype |
Autoantigens |
Randomized Controlled Trials |
Multicenter Studies |
Age Factors |
Chaperonin 60 |
Therapeutic Use |
Double-Blind Method |
Hypoglycemic Agents |
Therapeutic Use |
Kinetics |
Peptide Fragments |
Therapeutic Use |
Imunoterapija |
Sladkorna bolezen inzulin-odvisna |
Genotip |
Geni MHC razred II |
C-peptid |
Haperonin 60 |
Dvojnoslepa metoda |
Hipoglikemiki |
Naključno kontrolirane, klinične preiskave |
Avtoantigeni |
Kinetika |
Policentrične študije |
Starostni faktorji |
Peptidni deli
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
| Year | Impact factor | Edition | Category | Classification | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Impact factor
Select the library membership card:
DRS, in which the journal is indexed
| Database name | Field | Year |
|---|
| Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
|---|---|
| Buzzetti, Raffaella | ![]() |
| Cernea, Simona | ![]() |
| Petrone, Antonio | ![]() |
| Capizzi, Marco | ![]() |
| Spoletini, Marialuisa | ![]() |
| Zampetti, Simona | ![]() |
| Guglielmi, Chiara | ![]() |
| Venditti, Chiara | ![]() |
| Pozzilli, Paolo | ![]() |
| Battelino, Tadej | 13023 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
| Pickup location | Material status | Reservation |
|---|
Please wait a moment.
